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INTRODUCTION
When administering drug therapies to geriatric patients, it is
important to design a treatment regimen that accounts for their
decreased physical capacity and changes in physiological function
that occur with age (1). As there is substantial individual variation
with respect to age-related renal function deterioration, it is neces-
sary to evaluate the renal function of each patient before issuing
medication prescriptions.
Inulin clearance is considered to be the gold standard for
measuring glomerular filtration rate (GFR), an index of renal
function (2). However, measuring inulin clearance is labor- inten-
sive and time-consuming, and, as such, this index is rarely used in
routine clinical practice. In particular, it is difficult for certain pa-
tients, such as recumbent geriatric patients, to drink sufficient
amounts of water and to produce frequent blood and urine samples
after receiving inulin. Thus, the serum creatinine (SCr) value, an
endogenous marker, often serves as a substitute indicator of renal
function. One problem affecting the use of creatinine as an index is
that SCr is influenced by factors other than renal function, such as
sex, age, ethnicity, and nutritional status, since the quantity of cre-
atinine produced by the body is proportional to muscle mass. Addi-
tionally, as creatinine is secreted in part by the renal tubules sepa-
rately from glomerular filtration, the SCr value will not increase
until renal function sufficiently decreases (3), and renal tubular
creatinine secretion is influenced by low albumin values (4, 5).
Meanwhile, serum cystatin C protein (CysC) concentration,
which became a Japanese National Health Insurance adaptation in
October 2005, is dependent on GFR (6), and is not readily influ-
enced by factors, such as muscle mass, diet, or exercise habits.
Additionally, endogenous production remains constant regardless
of age or sex (7, 8). Therefore, CysC has been recognized as a
marker of early -stage renal dysfunction that has high clinical utility
(9, 10). SCr value measurements cannot accurately assess the ex-
tent of age-related decreases in renal function, but CysC levels in-
crease with age (11) ; hence, this index can be used for such assess-
ments (12, 13). However, there are several barriers to the use of
this assay, including its higher cost compared with SCr measure-
ment, the fact that only one CysC measurement per 3-month
period is reimbursable under the Japanese National Health Insur-
ance System, its ability to be influenced by medicines and thyroid
dysfunction (14-16), and the observation that increases in CysC
values peak in conjunction with end-stage renal failure due to its
metabolism/excretion outside the kidney (17). For these reasons,
CysC values have limited clinical application, and therefore ad-
hering to the most suitable, situation-specific uses of either CysC or
SCr values is essential when evaluating renal function.
Creatinine production is decreased in long-term recumbent pa-
tients and elderly people with poor nutritional status or low muscle
mass. For this reason, diminished renal function is not necessarily
reflected in SCr values. Creatinine clearance (CCr) calculated by
renal function estimation formulas using the SCr value may result in
overestimation. The SCr value is an excellent index of renal func-
tion that is simple, inexpensive, and reproducible, but is consid-
ered to be dependent on muscle mass. As the Cockcroft -Gault
(CG) formula (18) and other such formulas (19-21) do not account
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for muscle mass and degree of obesity, the use of estimated cre-
atinine clearance (eCCr) values can be problematic with respect to
geriatric patients since muscle mass decreases with age. As such,
the purpose of this study was to collect data from bedridden
elderly patients to investigate the relationship between eCCr
values and various detailed body composition data, including
muscle mass and body fat volume, and to establish a novel CCr
estimation formula for use in recumbent geriatric patients. The per-
formance of the new estimation formula was evaluated by comparing
eCCrvalues calculated using the new formula to the measured CCr
(mCCr) values based on a 24-hour urine collection method.
Next, the values of estimated glomerular filtration rates (eGFR)
based on the CysC or various CCr values were compared in order to
investigate which method is suitable to determine the renal func-
tion of bedridden patients. Horio et al. reported that the eGFR
based on the CysC (eGFR(CysC)) was compatible with the measured
GFR using inulin renal clearance (22). Since the inulin clearance
was not obtained in this study, we used eGFR(CysC) as an indicator of
renal function and compared the GFR(control)value obtained from the
mCCr value and other eGFR values, as calculated by CCr values
based on the SCr.
Finally, we evaluated the patients’ conditions based on the
Japanese Society of Nephrology chronic kidney disease (CKD)
severity classification using various GFR values, and evaluated our
new estimation formula in Japanese bedridden elderly patients.
METHODS
Study population
We studied 77 recumbent patients aged 65 or older who were
hospitalized at Naruto Yamakami Hospital between August 2014
and July 2016. Patients with missing limbs and those undergoing
treatment for infection were excluded. Since elderly people often
have multiple chronic diseases and take multiple drug combina-
tions, no exclusion criteria related to current diseases or concomi-
tant medications were established.
Assessment of renal function
1. Measurement of renal function
In this study, mCCr was based on the 24-hour urine collection
method (2) to accurately evaluate the patients’ renal functions. To
ensure precise urine collection, an indwelling bladder catheter was
inserted into all patients. To ensure the reliability of the urine collec-
tion, the excretion of urinary creatinine (UCr) in one day was
checked (23). Urine collection was initiated at a designated time
and then continued until the same time on the following day. Total
urine volume (mL/day) was measured after mixing the samples
thoroughly, and a portion of the urine collected was used to deter-
mine the UCr concentration (mg/dL). SCr (mg/dL) was meas-
ured in the morning before patients took meals, and mCCr (mL/
min) was calculated based on the following formula :
mCCr = (UCr × total urine volume) / (SCr × 1440)
Where, total urine volume is in mL.
2. Estimation of renal function
The CG equation (18) was used to calculate eCCr. The SCr value
used in the CG formula was determined colorimetrically using the
Jaffé rate assay. Therefore, it was necessary to convert the enzy-
matic SCr value (SCr(Enz)), which was measured using the creat-
inase-sarcosine oxidase-peroxidase method (24, 25), to a value
approximating the SCr value determined using the colorimetric
Jaffé assay, before applying the value to the CG formula. The
eCCr(Enz + 0.2) was calculated using the Jaffé assay-equivalent SCr
value. SCr(Enz + 0.2), obtained by adding 0.2 mg/dL to the SCr(Enz)
value, according to the method proposed by Horio and Orita (26).
With the CG equation, eCCr(Enz) and eCCr(Enz + 0.2) values were
estimated using formulas (A) and (B) below, respectively.
eCCr(Enz) = ((140-Age) × Weight) / (72 × SCr(Enz)) × 0.85 (in
women) ···(A)
eCCr(Enz + 0.2) = ((140-Age) × Weight) / (72 × (SCr(Enz) + 0.2)) × 0.85
(inwomen) ···(B)
Where, eCCr(Enz) and eCCr(Enz + 0.2) are in mL/min, age is in years,
and weight is in kg.
3. Development of a novel estimation formula
Multiple linear regression analysis was performed using mCCr
values as dependent variables, and eCCr(Enz + 0.2) values, serum albu-
min values, triceps skinfold thickness (TSF), arm muscle area
(AMA), skeletal muscle mass (SMM), hemoglobin values, and
body fat mass (BFM) as independent variables. Multicollinearity
was confirmed not to occur between independent variables based
on variance inflation factor (VIF) values. Parameters having sub-
stantial impact on the dependent variable (mCCr) based on the
absolute value of the standard partial regression coefficient (β)
were selected and new estimation formulas (C) and (D) were cre-
ated in the results.
SCr and UCr values were determined using the enzymatic
method with an Aqua Auto-Kainos CRE-II reagent (Kainos Co.,
Tokyo, Japan). CysC values were measured using the gold colloid
colorimetric method with the Nescoat GC Cystatin C Kit (Alfresa
Pharma, Osaka, Japan). Several types of automatic analyzers were
used as measurement devices (AU5800 (Beckman Coulter, Tokyo,
Japan) ; JCA-BM 9130, JCA-BM 8030 (JEOL Ltd., Tokyo, Japan)).
Physical measurement method
The bioelectrical impedance method is atechnique for measur-
ing body composition by determining a resistance value (imped-
ance) that is created by the body from the application of a weak and
harmless electrical current of approximately 1 mA. The In Body S20
(INBODY JAPAN CORPORATION, Tokyo, Japan) body composi-
tion analyzer was used to measure physical metrics, such as the
SMM and BFM. A total of 8 touch type electrodes were meas-
ured : 1 electrode on each of the thumb and middle fingers on the
left and right hands (4 points) and 1 electrode on the inner and
outer temporal surfaces of the left and right heels (4 points).
Electrode measurements were taken with patients lying supine on a
bed.
TSF and arm circumference (AC) measurements were ob-
tained at the level of the midpoint between the acromion and olecra-
non processes in the non-dominant and non-paralyzed arm. AC
(cm) and TSF (mm) were measured using the insertape and adi-
pometer (Abbott Japan Co., Ltd., Tokyo, Japan), and the average of
three readings in a single place was used. AMA (cm2) was calcu-
latedbasedonthe following formula(27) :
AMA=(AC -3.14×TSF)2/(4×3.14)
GFR (mL/min/1.73 m2) Estimation Formulas
CCr (mL/min) was converted to GFR (mL/min/1.73m2) using
the following GFR estimation formula. A body surface area (BSA)
correction was performed using the DuBois formula (28), as fol-
lows :
BSA = 0.007184 × Height 0.725 × Weight0.425
Where, BSA is in m2, height is in cm, and weight is in kg.
Japanese GFR estimation formula using serum CysC (2, 22) :
eGFR(CysC) = (104 × CysC-1.019 × 0.996Age × 0.929 (in women) -8
···Equation1
Where, CysC is in mg/L.
Formula to estimate GFR(control) from mCCr values (2, 19)
GFR(control) = 0.715 × mCCr × 1.73/BSA ···Equation2
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Japanese GFR estimation formula using SCr(Enz) values (2, 19)
eGFR(creat) = 194 × Scr(Enz) - 1.094 × Age - 0.287 × 0.739 (in women)
···Equation3
Estimation formula using eCCr(Enz) values (2, 19) calculated by the
CG formula with SCr(Enz) values (18)
eGFR(CG) = 0.789 × eCCr(Enz) × 1.73/BSA ···Equation4
Novel estimation formula using eCCr(Enz + 0.2) values corrected using
TSF (eCCr(TSF))
eGFR(TSF) = 0.789 × eCCr(TSF) × 1.73/BSA ···Equation5
Novel estimation formula using eCCr(Enz + 0.2) values corrected using
BFM (eCCr(BFM))
eGFR(BFM) = 0.789 × eCCr(BFM) × 1.73/BSA ···Equation6
Statistical analysis
The minimum required sample size was calculated a priori to
be 31 patients, using A-priori Sample Size Calculator for Multi-
ple Regression software version 4.0 (29), based on an α=0.05,
power of 80%, and a large effect size (0.35) with 2 predictors.
The results are expressed as the mean standard deviation
(meanSD). The intercept and slope of the regression equation of
eCCr(y) and mCCr(x) and the coefficient of determination R2 were
used to evaluate the predicted performance.
A Bland-Altman analysis (30) was performed to assess the
degree of agreement between the mCCr and eCCr values. The
average of the differences between the eCCr and mCCr values was
taken as bias or systemic error and the standard deviation (SD) of
the differences was taken as an index of precision. The average
value2 SD was taken as the 95% limits of agreement (LOA). The
proximity of the average of the differences between the eCCr and
mCCr values from zero was considered to be highly consistent.
The accuracy of the eCCr values obtained was defined as the per-
centage of patients for which errors between the mCCr and eCCr
values were within30%.
A one-way analysis of variance (ANOVA) was conducted using
GFR (mL/min/1.73 m2) values calculated by a different method as
the dependent variable and the calculation method as the group
variable, and multiple comparisons tests were conducted for all
pairs. Patients’ GFR (mL/min/1.73 m2) values calculated by each
method were also classified by disease stage based on the Japanese
Society of Nephrology CKD severity classification (2), as fol-
lows : G1 (GFR90, normal), G2 (GFR 60-89, normal to mild
deterioration), G3a (GFR 45-59, mild to moderate deteriora-
tion), G3b (GFR 30-44, moderate to pronounced deterioration), G4
(GFR 15-29, pronounced deterioration) and G5 (GFR15, end-
stage renal failure). The degree of agreement was compared using
Pearson’s x2 test.
A p-value of0.05 was considered to be statistically significant.
Statistical analyses were performed using the JMP 11.0 software
(SAS Institute, Cary, NC, USA).
RESULTS
The backgrounds of the 77 subjects (34 men, 43 women) tar-
geted by this study are shown in Table 1. The measured mean SMM
was 17.182.98 kg in men and 12.142.32 kg in women (p
0.0001), with a statistically significant difference between the male
and female patients. The mean SCr value was 0.890.44 mg/dL in
men and 0.700.45 mg/dL in women. Male patients tended to
have slightly higher SCr values, although this difference was not
significant (p = 0.06). No differences between the sexes were ob-
served with respect to the other measurement items.
A simple linear regression analysis using mCCr values as the
dependent variable and eCCr values as the independent variable
resulted in (a) eCCr(Enz) values calculated using SCr(Enz) values (R2 =
0.74), or (b) eCCR(Enz + 0.2) values calculated using SCr(Enz + 0.2) values
(R2 = 0.72). Significant positive correlations were observed be-
tween the mCCr and both eCCr(Enz) and eCCr(Enz + 0.2) values (p
0.0001) (Figures 1 [a] and [b]). A favorable linear regression equa-
tion (y = 1.07x + 1.00, R2 = 0.72, p 0.0001) was obtained in
Figure 1 (b) when the SCr(Enz + 0.2) values were used to estimate
eCCr. Figures 2 (a) and (b) show the Bland-Altman plot in which
the average of the mCCr and eCCr values are plotted on the x-axis
and the difference between the mCCr and eCCr values are plotted
on the y-axis. When the SCr(Enz) values were used in method (a),
the average difference was 11.6 mL/min and the standard devia-
tion was 15.3 mL/min (Table 2). In contrast, the average differ-
ence was smaller ( - 3.5711.1 mL/min) in method (b) when the
SCr(Enz + 0.2) values were used (Table 2). Thus, the eCCr(Enz + 0.2) values
Table 1. Patient characteristics
Men
(MeanSD)
Women
(MeanSD) (MeanSD)
All
(minimum - median - maximum)
Number 34 43 77
Age (years) 82.95.75 83.89.47 83.40.81 (65 - 85 - 98)
BMI (kg/m2) 18.82.99 19.93.62 19.43.38 (10.3 - 19.6 - 27.0)
Alb (g/dL) 2.850.57 2.960.47 2.910.52 (1.9 - 2.9 - 4.4)
SCr (mg/dL) 0.890.44a) 0.700.45a) 0.780.45 (0.17 - 0.65 - 2.26)
BUN (mg/dL) 22.410.5 23.615.3 23.013.3 (4.3 - 20.9 - 74.1)
CysC (mg/L) 1.860.67 1.800.77 1.820.72 (0.61 - 1.67 - 4.24)
mCCr (mL/min) 46.8421.87 39.7719.71 42.8920.86 (6.67 - 42.42 - 97.99)
eCCr(Enz) (mL/min) 55.1024.93 54.0732.13 54.5228.99 (10.45 - 50.64 - 169.58)
TSF (mm) 6.774.44 7.864.93 7.404.73 (1.0 - 6.0 - 23.0)
BFM (kg) 17.217.18 18.125.44 17.746.19 (6.5 - 18.4 - 38.0)
AMA (cm2) 32.118.56 29.857.86 30.818.19 (6.1 - 29.9 - 51.7)
SMM (kg) 17.182.98* 12.142.32* 14.293.61 (6.1 - 13.8 - 23.9)
BMI : Body mass index ; Alb : Serum albumin ; SCr : Serum creatinine ; BUN : Blood urea nitrogen ; CysC : serum cystatin C ; mCCr : measured
creatinine clearance ; eCCr(Enz) : creatinine clearance estimated using the Cockcroft -Gault formula ; TSF : triceps skinfold thickness ; BFM : body fat
mass ; AMA : arm muscle area ; SMM : skeletal muscle mass ;
Data are expressed as meanstandard deviation (SD). a) p = 0.06, *p0.0001
The Journal of Medical Investigation Vol. 65 August 2018 197
calculated with SCr(Enz + 0.2) in method (b) were used for the subse-
quent analyses.
Next, a multiple regression analysis was performed using the
mCCr values as the dependent variable and the eCCr(Enz + 0.2) values,
serum albumin values, TSFs, AMAs, SMM, hemoglobin values,
and BFMs as the independent variables. The multiple linear re-
gression indicated that the mCCr values were positively corre-
lated with the eCCr(Enz + 0.2) and serum albumin values and nega-
tively correlated with the BFMs and TSFs (Table 3). The statisti-
cally significant independent variables, for which the absolute
values of the standard partial regression coefficients (β) were rela-
tively large (β0.2), were selected after confirming that there were
no instances of multicollinearity with enough low VIF values (VIF
2.0 in Table 3). Under these conditions in the multiple regression
analysis, eCCr(Enz + 0.2) (β= 0.98), TSF (β= -0.24), and BFM (β= -0.25)
were selected as the independent variables to predict the CCr val-
ues. Since both TSF and BFMmeasurements are indices of body
fat volume, a CCr estimation formula (C) or (D) using eCCr(Enz + 0.2)
values and either TSF or BFM was built with high performance.
eCCr(TSF) = 5.75 + 1.11 × eCCr(Enz + 0.2) -0.93 × TSF ···(C)
n = 73, R2 = 0.768, s = 10.4, F = 116.0
eCCr(BFM) = 16.5 + 1.14 × eCCr(Enz + 0.2) -1.08 × BFM ···(D)
n=54,R2=0.761, s=9.89,F=81.3
Where,eCCr is inmL/min,TSFis inmmandBFMis inkg.
Figure 1. Correlation between mCCr and eCCr values obtained by
different methods.
(a) eCCr(Enz) was calculated using the SCr(Enz) value determined by the
enzymatic method ; (b) eCCr(Enz + 0.2) was calculated using the SCr(Enz + 0.2)
value obtained by adding 0.2 mg/dL to the SCr(Enz) value ; (c) eCCr(TSF)
was corrected eCCr(Enz + 0.2) with triceps skinfold thickness (TSF) ; (d)
eCCr(BFM) was corrected eCCr(Enz + 0.2) with body fat mass (BFM). Solid
lines represent the line of identity.
Figure 2. Bland-Altman plots showing the differences between mCCr
and eCCr values obtained by the different methods.
(a) eCCr(Enz) was calculated using the SCr(Enz) values determined by the
enzymatic method ; (b) eCCr(Enz + 0.2) was calculated using the SCr(Enz + 0.2)
value obtained by adding 0.2 mg/dL to the SCr(Enz) value ; (c) eCCr(TSF)
was corrected eCCr(Enz + 0.2) with triceps skinfold thickness (TSF) ; (d)
eCCr(BFM) was corrected eCCr(Enz + 0.2) with body fat mass (BFM). The
solid line indicates the mean difference, and the dashed lines depict the
upper and lower 95% limits of agreement.
Table 2. Mean difference between mCCr and eCCr values and accuracy of the eCCr measurement in the Bland-Altman analysis
Equations Mean of difference
SD
(mL/min)
95% limits of agreement
(mL/min)
Accuracy within 30%
(%)
eCCr(Enz) 11.615.3 8.16 - 15.1 71.4
eCCr(Enz + 0.2) -3.5711.1 -6.08 - -1.05 70.1
eCCr(TSF) -0.08710.2 -2.47 - 2.30 75.3
eCCr(BFM) 0.0159.7 -2.63 - 2.66 77.8
mCCr, measured creatinine clearance ; eCCr, estimated creatinine clearance.
eCCr(Enz) = [(140 - Age) × Weight]/[72 × SCr(Enz)] × 0.85 (if women)
eCCr(Enz + 0.2) = [(140 - Age) × Weight]/[72 × (SCr(Enz )+0.2)] × 0.85 (if women)
eCCr(TSF) = 5.75 + 1.11 × eCCr(Enz + 0.2) - 0.93 × TSF
eCCr(BFM) = 16.5 + 1.14 × eCCr(Enz + 0.2) - 1.08 × BFM
Where, eCCr is in mL/min, age is in years, weight is in kg, SCr is in mg/dL, TSF is in mm, and BFM is in kg.
In the Bland-Altman analysis, the accuracy of the eCCr measurement was defined as the percentage of patients with eCCr values within30% of
the mCCr values. Data are expressed as meanstandard deviation (SD).
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In a simple linear regression analysis, the coefficients of de-
termination between the dependent variable (i.e., the mCCr values)
and the independent variables (i.e., eCCr(TSF) and eCCr(BFM)) were
0.767 and 0.761, respectively. Both the eCCr(TSF) and eCCr(BFM) val-
ues demonstrated a significantly positive correlation with the
mCCr values (p0.0001) (Figures 1 (c) and (d)).
A Bland-Altman plot of the mCCr values and either the eCCr(TSF)
or the eCCr(BFM) values is shown in Figures 2 (c) and (d). The
analysis results are summarized in Table 2. The average difference
between the eCCr(TSF) values was 0.087 mL/min, with a SD of 10.2
mL/min. For the eCCr(BFM) values, the average difference was
0.015 mL/min and the SD was 9.70 mL/min, both of which were
smaller than those of the eCCr(Enz) or the eCCr(Enz + 0.2) values. The
accuracy of the eCCr values was defined as the percentage of
patients for which the degree of error between their corresponding
mCCr and eCCr values fell within30%, and the 4 groups were
compared relatively. As a result, the accuracy of the eCCr(BFM)
values was the highest at 77.8%, followed by the eCCr(TSF) values at
75.3%. Compared to these, the accuracy of eCCr(Enz) and eCCr(Enz+0.2)
were lower at 71.4% and 70.1%, respectively (Table 2).
Next, using the obtained CCr (mL/min) values, the estimated
GFR (mL/min/1.73 m2) value for each patient was calculated
based on the GFR estimation formulas described above (Equation 1
through Equation 6). Box-and-whisker plots of the distribution of
GFR (mL/min/1.73 m2) values in the 6 eGFR groups are shown in
Figure 3. A one-way ANOVA was performed with the GFR estima-
tion method as a group variable and the derived GFR values as
dependent variables. Significant differences were observed be-
tween the groups. Further, to determine which groups exhibited
differences, a nonparametric, multiple comparison test was per-
formed using the Steel -Dwass method. As a result, no significant
difference was observed between the eGFR(CysC) group and the
GFR(control) group. The mean value of eGFR(creat) group was signifi-
cantly higher than those of all other groups (p0.05). No signifi-
cant differences were observed between the GFR(control) and the
eGFR(TSF) groups, the GFR(control) and the eGFR(BFM) groups, or the
eGFR(TSF) and the eGFR(BFM) groups (Figure 3).
Furthermore, each patient’s degree of renal dysfunction was
classified by stage based on the Japanese Society of Nephrology
CKD severity classification, and the degrees of coincidence were
compared using Pearson’s x2 test based on the derived GFR values
(mL/min/1.73 m2). The results are described in Figure 4. When
the eGFR(CysC) value was used to evaluate the patient’s renal func-
tion, it was shown that only 6 (7.9%) patients hadnormal or nearly
normal renal functions, while 71 patients (92.1%) exhibited a
degree of renal failure. In detail, 2 (2.6%), 4 (5.3%), 11 (14.5%), 30
(39.5%), 24 (31.6%), and 5 (6.6%) patients were classified as having
CKD stages G1, G2, G3a, G3b, G4, and G5, respectively. Using the
GFR(control) values derived from the mCCr values based on the 24-
hour urine collection method, there were 2 (2.6%), 8 (10.4%), 19
(24.7%), 22 (28.6%), 18 (23.4%), and 8 (10.4%) patients classified as
having CKD stages G1, G2, G3a, G3b, G4, and G5, respectively. It
was shown that thepatterns of CKD severity classification were not
significantly different between the eGFR(CysC) and GFR(control) groups.
Therefore, the CKD severity patterns of the other 4 eGFR groups,
which were calculated with eCCr values based on the SCr, were
compared with those of the GFR(control)group. When evaluating with
the eGFR(creat) value recommended by the Japanese Society of
Nephrology CKD Guide (2), more than 60% of patients were classi-
fied as having G1 (37.7%) and G2 (26.0%), whereas, many patients
were classified as normal or nearly normal regardless of their poor
renal function. In contrast, the data in the GFR(control) group showed
that 13% of patients were classified as having both G1 and G2 stages,
thereby accounting for approximately 20% of the eGFR(creat) patient
group. In the eGFR(CG) group, the proportion of patients classified
within the normal range was also relatively higher that the propor-
tion in the GFR(control)group, as the proportion of G1 and G2 among
Table 3. Relationship between mCCr and various factors : multiple regression analysis
Independent variables Partial correlationcoefficient (β) 95% CI VIF p-value
eCCr (Enz + 0.2) 0.98 1.00 - 1.39 1.58 0.0001
BFM -0.25 -1.4 - -0.28 1.77 0.0041
TSF -0.24 -1.7 - -0.32 1.69 0.0052
Alb 0.15 0.05 - 13.7 1.39 0.048
AMA -0.077 -0.62 - 0.23 1.8 0.37
Hb 0.057 -1.51 - 3.06 1.77 0.50
SMM 0.054 -0.55 - 1.14 1.45 0.48
CI : confidence interval ; VIF : variance inflation factor ; eCCr(Enz+0.2) : creatinine clearance estimated using the Cockcroft -Gault formula with SCr to
which we added 0.2 mg/dL to the enzymatically measured value ; BFM : body fat mass ; TSF : triceps skinfold thickness ; Alb : serum albumin ;
AMA : arm muscle area ; Hb : hemoglobin value ; SMM : skeletal muscle mass.
Figure 3. Box-and-whisker plots of GFR(control) and eGFR values
obtained by different methods.
The equations to estimate GFR values were described in the methods.
eGFR(CysC), based on the Japanese estimation formula using CysC ;
GFR(control), based on the mCCr value ; eGFR(creat), based on the Japanese
GFR estimation formula ; eGFR(CG), based on eCCr(Enz) estimated by the
Cockcroft -Gault formula with enzymatic SCr ; eGFR(TSF), based on
eCCr(TSF) ; eGFR(BFM), based on eCCr(BFM). The box-and-whisker plots
represent the medians and interquartile ranges. Medians are indi-
cated by the lines inside the boxes. Boxes indicate the interquartile
range. Whiskers indicate the maximum and minimum values. Data were
analyzed using one-way ANOVA followed by the Steel -Dwass test. A
significant difference (p0.05) was observed between the eGFR(creat)
group and all other groups. No significant differences were observed
between the other groups.
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patients was 11.7% and 19.5%, respectively. Meanwhile, no signifi-
cant difference in CKD classification patterns in the GFR(control)
group was observed in either the eGFR(TSF) group (p=0.640) or the
eGFR(BFM) group (p=0.406), based upon the new GFR estimation
formula developed in this study.
DISCUSSION
When administering drug therapy, overestimation of renal func-
tion leads to adverse drug events, while underestimation can lead to
improper timing of administration. Therefore, accurate renal func-
tion assessment is essential for ensuring safe and efficacious drug
therapy. Normally, SCr values are used as an index of renal func-
tion. However, renal function assessments based on SCr values
have low reliability, particularly in geriatric patients. Since sys-
temic SMM decreases with age, the accuracy of estimation formulas
based on SCr values and parameters related to muscle mass could
potentially be improved with respect to geriatric patients. There-
fore, in this study, we attempted to develop a novel CCr estimation
formula to correct the CG formula using physical measurement
data for use in elderly bedridden patients first, and then evaluated
the clinical utility of the formula.
The In Body S20 apparatus was used during this study to accu-
rately measure SMM and BFM. However, due to the high cost of
the In Body S20, only a limited number of medical institutions and
facilities make use of this system, and using the system in routine
clinical practice or in elder care facilities is difficult. Furthermore,
even with simple body composition meters/adipometers, their use
can be difficult in bedridden patients because of the need to step
onto the measurement platform or grasp the electrode. Thus, in-
stead of measuring SMM and BFM with special equipment, we
considered substituting physical measurement indices, such as
the AMA and TSF, which are routinely measured by clinical nutri-
tionists to assess the nutritional status of geriatric patients.
In this study, we demonstrated that BMF or TSF, markers of
body fat volume, were useful in correcting the estimation of renal
function in elderly patients. A potential reason for these observa-
tions may be the fact that this study included bedridden geriatric
patients, who tend to exhibit reduced physical activity in conjunc-
tion with aging, often suffer from additional conditions, and usually
have an altered nutritional status. Elderly people are often in a
qualitatively obese state (increased proportion of adipose tissue) as
muscle mass decreases while body fat mass increases with age
(31). We can infer that these factors likely have a multifaceted
impact on bedridden geriatric patients. Furthermore, the results of
this study are consistent with the results of reports on body fat and
renal function deterioration (32-35).
According to the results of the present study, it was found that
the patients’ renal function can be assessed most accurately using
our new eCCr(BFM) estimation formula based on the CG formula that
was corrected using SCr(Enz + 0.2) values and BFM (Table 2). The
eCCr(TSF) values calculated using TSF also had a high degree of
agreement with the mCCr similar to the eCCr(BFM) values (Table 2).
Generally, in the case of drugs that are excreted from the kidney,
the method of drug administration should be changed according to
the CCr value of individual patients, as stated in the package insert.
Therefore, the eCCr(BFM) and eCCr(TSF) values may be useful for the
prescriber to adjust the drug dosage.
As shown in Figure 3, the multiple comparisons test revealed no
significant differences between the GFR(control) group and the
eGFR(TSF) or eGFR(BFM) groups, and no difference was observed
between the eGFR(TSF) group and the eGFR(BFM) group. There-
fore, it is clear that substituting the anthropometrical TSF values is
sufficiently feasible in cases where BFM cannot be measured using
the bioelectrical impedance method from bedridden patients. In
addition, it was also suggested that high TSF values were not re-
flective of edema due to renal dysfunction in these patients.
The severity of patients’ kidney dysfunction has traditionally
been classified using the Japanese Society of Nephrology CKD
severity classification (2). It has been reported that the measured
GFR value, which is based on inulin, and the eGFR(CysC) value are
similar (22). In eGFR(CysC), which uses values that are similar in
nature to that obtained by measuring inulin, 92% of patients were
classified as having CKD stage G3 or higher, exhibiting a moderate
or more severe reduction in renal function. Since there was no
difference in classification pattern in the GFR(control) group when
using the mCCr and the eGFR(CysC) group, which used values that
are similar in nature to that obtained by measuring inulin, we com-
pared other methods to the GFR(control) value, which we considered
the control group. In so doing, we found that using eGFR(creat),
which is usually used for CKD severity classification, resulted in
60% of patients being classified as having stage G1 to G2. Since
eGFR(creat) is clearly different from the classification pattern deter-
mined using other methods, we determined that eGFR(creat) is not
suitable for elderly people. Furthermore, when compared to
GFR(control), eGFR(CG) resulted in more patients being considered
normal. It was revealed that the eGFR(creat) and the eGFR(CG) groups
did not reflect the actual renal function of patients. Consequently,
making these values an indicator of renal dysfunction might lead
delaying the timing of treatment and suboptimal results with regular
dosages for patients. Meanwhile, the eGFR(TSF) and eGFR(BFM)
groups showed the classification pattern closest to the GFR(control)
group derived from mCCr (Figure 4). Furthermore, no difference
was found in the classification patterns of eGFR(CysC), GFR(control),
and eGFR(TSF). Therefore, when mCCr or CysC cannot be meas-
ured, eCCr(TSF) values calculated using TSF can be an alternative
method of renal function evaluation in bedridden elderly patients.
Based on these results, we named this new TSF-based estima-
tion formula the “Naruto” formula, which is named after our
hospital.
eCCr(Naruto) = 5.75 + 1.11 × eCCr(Enz + 0.2) -0.93 × TSF
= 5.75 + 1.11 × [(140 -Age) × Weight] / [72 × (SCr(Enz) +
0.2)]× 0.85 (in women) -0.93 × TSF
Figure 4. Contingency analysis of chronic kidney disease severity by
GFR value.
The GFR values were estimated by the equations described in the
methods. GFR stages : descriptions and range (mL/min/1.73 m2) were
according to the Japanese Society of Nephrology CKD severity classifica-
tion as follows, G1 : GFR90, G2 : GFR60~89, G3a : GFR45~59, G3b :
GFR30~44, G4 : GFR15~29, G5 : GFR<15. To enhance the interpretabil-
ity of the results, a Pearson Chi square analysis was used. Mosaic plots
shows that the eGFR(TSF) or eCCr(BFM) groups were most similar to the
classification patterns observed for the GFR(control) group.
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eGFR(Naruto) = 0.789 × eCCr(Naruto) × 1.73 / BSA
Where, eCCr is in mL/min, Age is in year, Weight is in kg, SCr is in
mg/dL, TSF is in mm, eGFR is in mL/min/1.73 m2, and BSA is in
m2.
Because the Naruto formula utilizes clinical laboratory values and
routine nutrition management metrics in bedridden geriatric pa-
tients, eCCr(Naruto) values can be calculated easily without additional
costs or the utilization of specialized resources. The eGFR(Naruto)
values that derive from eCCr(Naruto) values have been demonstrated to
correlate with CKD severity classification corresponding to GFR(control)
values when evaluating patients’ renal functions. These observa-
tions indicate that renal function determinations using the Naruto
formula in bedridden geriatric patients is extremely useful from the
perspective of drug therapy optimization. We expect that this for-
mula will be utilized in clinical practice.
Limitations of this study include the fact that results were ob-
tained from a single elder care facility, and the fact that the patients’
concomitant medications and prior medical histories were not con-
sidered in our assessment. In this study, mCCr was considered to be
the true renal function of the patient. There is a large difference
between mCCr value and inulin clearance value, and correction is
reportedly necessary (19, 26, 36). However, no correction method
has been established for elderly people or elderly people with
sarcopenia (37). Furthermore, the difference between the mCCr
value and the inulin clearance value increases in accordance with
renal function deterioration (19, 26, 38). Furthermore, since the
SCr value is included in the mCCr formula, a bedridden elderly
patient with a low SCr value may possibly result in the overestima-
tion of mCCr itself. Since the SCr value is also used for the new
estimation formula, the problem of using the SCr value has not
been resolved. In cases of low SCr value, it is unclear the extent to
which mCCr correlates with inulin clearance. Accordingly, further
verification of our results based on data obtained from additional
patients and facilities is necessary.
CONCLUSION
In the present study, we developed a novel equation to update the
CG equation, called the “Naruto” formula, for estimating the CCr
when evaluating the renal function of Japanese bedridden elderly
patients. In using eCCr(Naruto) values corrected by the anthro-
pometrical TSF value, we were able to derive the eGFR(Naruto)
values, which sufficiently correlated with the CKD severity classifica-
tion pattern corresponding to the real GFR. The Naruto formula
can be clinically useful for managing drug therapies of geriatric
patients by determining their renal functions without the use of
expensive equipment and avoiding incurring additional medical
expenses. Notably, as the SCr value is included in the mCCr for-
mula, a bedridden elderly patient with a low SCr value may possibly
suffer from the overestimation of the mCCr itself. Since the SCr
value is also used for the new estimation formula, we have not
resolved the concern of using the SCr value.
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